Zealand Pharma A/S
CSE:ZEAL
Zealand Pharma A/S
Total Current Assets
Zealand Pharma A/S
Total Current Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Total Current Assets
kr8.5B
|
CAGR 3-Years
70%
|
CAGR 5-Years
43%
|
CAGR 10-Years
31%
|
|
|
Genmab A/S
CSE:GMAB
|
Total Current Assets
kr27.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
15%
|
CAGR 10-Years
26%
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Total Current Assets
€1.1B
|
CAGR 3-Years
10%
|
CAGR 5-Years
12%
|
CAGR 10-Years
35%
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Total Current Assets
kr5.8B
|
CAGR 3-Years
7%
|
CAGR 5-Years
55%
|
CAGR 10-Years
16%
|
|
|
Bioporto A/S
CSE:BIOPOR
|
Total Current Assets
kr83.9m
|
CAGR 3-Years
9%
|
CAGR 5-Years
19%
|
CAGR 10-Years
9%
|
|
|
Saniona AB
STO:SANION
|
Total Current Assets
kr324.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
44%
|
CAGR 10-Years
38%
|
|
Zealand Pharma A/S
Glance View
Zealand Pharma A/S is a Danish biotechnology company that has carved a niche in the medical field by focusing on the design and development of innovative peptide-based medicines. Established in 1998 and headquartered in Copenhagen, the company is driven by a singular mission: to improve patients' lives through impactful treatments. Zealand's expertise lies in peptide therapeutics, a compelling segment of biopharmaceuticals due to their ability to mimic biological processes with high specificity and efficacy. The company has a keen focus on addressing unmet medical needs, particularly in the treatment of metabolic and gastrointestinal diseases. With a robust pipeline that ranges from early-stage research to late-stage clinical trials, Zealand Pharma leverages its proprietary technology to discover and develop novel pharmaceuticals that can be game-changers in their respective therapeutic areas. Zealand Pharma's business model centers around the development and commercialization of its proprietary medicines, both independently and through strategic partnerships. By collaborating with larger pharmaceutical companies, Zealand enhances its global commercialization capabilities and mitigates the financial risks inherent in drug development. For instance, the company has partnered with multinational corporations, allowing it to tap into resources for advanced research, regulatory processes, and worldwide distribution systems. Revenue streams are diversified through milestone payments, royalties, and direct sales, ensuring a steady inflow of cash that supports continued innovation. This strategic approach not only sustains its operations but also propels its mission of delivering transformative healthcare solutions. In essence, Zealand Pharma thrives at the confluence of science and strategy, driving both its financial health and its contributions to the biopharmaceutical landscape.
See Also
What is Zealand Pharma A/S's Total Current Assets?
Total Current Assets
8.5B
DKK
Based on the financial report for Dec 31, 2024, Zealand Pharma A/S's Total Current Assets amounts to 8.5B DKK.
What is Zealand Pharma A/S's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
31%
Over the last year, the Total Current Assets growth was 379%. The average annual Total Current Assets growth rates for Zealand Pharma A/S have been 70% over the past three years , 43% over the past five years , and 31% over the past ten years .
You don't have any saved screeners yet